Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Clin Cancer Res. 2014 Mar 31;20(11):3033–3043. doi: 10.1158/1078-0432.CCR-13-3140

Figure 1. Study profile.

Figure 1

BRAF-mutated cases were excluded to assess the prognostic role of KRAS mutation in BRAF-wild type tumors. * Includes patients with KRAS-mutated tumors (n=332) enrolled post-study modification (see Methods), of whom 97% received FOLFOX.